The Syneos Health Podcast

CORONAVIRUS SPECIAL EDITION, Episode 4: Clinical Trials Through Pandemics

March 24, 2020 Jeffrey Stewart, Lou Boccumini
The Syneos Health Podcast
CORONAVIRUS SPECIAL EDITION, Episode 4: Clinical Trials Through Pandemics
Chapters
The Syneos Health Podcast
CORONAVIRUS SPECIAL EDITION, Episode 4: Clinical Trials Through Pandemics
Mar 24, 2020
Jeffrey Stewart, Lou Boccumini

In the midst of the COVID-19 pandemic, late stage clinical trials are at risk of disruption as shelter-in-place and more restrictive lockdown requirements roll out across the globe. How can these trials continue if patients can’t get to the clinic?

In this episode in our Coronavirus Special Edition Series, Lou Boccumini, head of the infectious disease team at Syneos Health, discusses ways that developers can maintain continuity of their clinical trials during a pandemic – and how to create resiliency in their clinical trials for the future.

Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.

Like what you’re hearing?  Be sure to rate and review us!  

We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com

* This episode was recorded on 3/19/2020.

Show Notes

In the midst of the COVID-19 pandemic, late stage clinical trials are at risk of disruption as shelter-in-place and more restrictive lockdown requirements roll out across the globe. How can these trials continue if patients can’t get to the clinic?

In this episode in our Coronavirus Special Edition Series, Lou Boccumini, head of the infectious disease team at Syneos Health, discusses ways that developers can maintain continuity of their clinical trials during a pandemic – and how to create resiliency in their clinical trials for the future.

Stay tuned for more installments of the Coronavirus Special Edition Series, which will explore, from an operational standpoint, the impact of COVID-19 on the biopharma industry, the challenges for rapid R&D in an outbreak environment, and the opportunities to leverage technology and innovation to address these critical issues. Additional materials and insights can also be found in our COVID-19 Resource Center.

If you want access to more future-focused, actionable insights to help biopharmaceutical companies better execute and succeed in a constantly evolving environment, visit the Syneos Health Insights Hub. The perspectives you’ll find there are driven by dynamic research and crafted by subject matter experts focused on real answers to help guide decision making and investment. You can find it all at insightshub.health.

Like what you’re hearing?  Be sure to rate and review us!  

We want to hear from you!  If there’s a topic you’d like us to cover on a future episode, contact us at podcast@syneoshealth.com

* This episode was recorded on 3/19/2020.